Effects of prostaglandin E2 analogue suppository on blood loss in suction abortion.
The purpose of the present clinical investigation was to determine the effect of preoperative treatment with a long-acting prostaglandin suppository containing 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 on uterine blood loss in patients undergoing preoperative cervical dilatation before transcervical abortion. Ninety-five young women in the ninth to 14th week of gestation were randomly assigned to one of two groups. Patients in group 1 were treated with a long-acting prostaglandin suppository and group 2 patients acted as control subjects. At the end of three hours, patients in both groups underwent abortion with careful intraoperative measurement of blood loss in both groups. The blood loss in the prostaglandin-treated group was significantly lower than that in the control group (69.0 +/- 14.1 mL versus 151.1 +/- 26.6 mL). The difference in intraoperative blood loss was observed at all gestations between nine and 14 weeks. There was significantly greater dilation of the cervix after prostaglandin treatment (mean difference, 4.58 mm; P less than .005).
D015064:16,16-Dimethylprostaglandin E2 / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000627:therapeutic use; D000028:Abortion, Induced; D002584:Cervix Uteri / Q000187:drug effects; D004106:Dilatation; D005260:Female; D006801:Humans; D011247:Pregnancy; D011292:Premedication; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage*; D013488:Suppositories; D014592:Uterine Hemorrhage / Q000517:prevention & control*
D011459:Prostaglandins E, Synthetic; D013488:Suppositories; C025505:meteneprost; D015064:16,16-Dimethylprostaglandin E2